Clinical evaluation of tibric acid (CP 18,524) a new hypolipidemic agent

Tibric Acid was given to thirteen volunteers (twelve patients with hyperlipoproteinemia and one normal subject) for a period of six months. The drug was well tolerated and it was effective in one daily administration of 500 mg in mild forms of hypertriglyceridemia. Patients with more severe hypertriglyceridemia or with mixed forms of hyperlipoproteinemia (type II b), proved to be rather resistant to treatment. In these, splitting of the dosage into three-four daily administrations achieved better results. The working hypothesis that tibric acid may be effective through a prolonged stimulation of liver glycerophosphate dehydrogenase cannot be fully supported by this study, and it is likely that tibric acid has other mechanisms of action.